{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058209","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.508172+00:00","generated_at":"2026-06-02T02:40:33.460870+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Terns Pharma Q1 net loss $22.4M; pipeline data expected H2 2024","bullets":["Net loss $22.4M ($0.30 per share) vs $21.5M ($0.31) in Q1 2023; R&D expense $18.6M.","Cash $240.7M at March 31, 2024, down from $263.4M; runway into 2026.","Interim TERN-701 CARDINAL dose-escalation data expected 2H24; FDA Orphan Drug Designation granted.","Top-line 28-day weight loss data from TERN-601 Phase 1 obesity trial expected 2H24.","Leadership: Melita Sun Jung appointed CBO, Scott Harris appointed CDO; Erin Quirk departing as president/R&D head."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058209","json":"https://secwatch.observer/filing/0000950170-24-058209.json","markdown":"https://secwatch.observer/filing/0000950170-24-058209.md","text":"https://secwatch.observer/filing/0000950170-24-058209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017024058209/0000950170-24-058209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017024058209/tern-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:40:33.460870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed55af854090bb582df0c4f2aec89dc7ca65f8a2","claim":"Terns Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income $22.4 million, EPS $(0.30).","evidence_excerpt":"Net loss was $22.4 million for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017024058209/0000950170-24-058209-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$22.4 million"},{"label":"EPS","value":"$(0.30)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}